EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas

Jacob D Soumerai iD, Catherine S Diefenbach iD, Deepa Jagadeesh, Adam Asch, Abhijeet Kumar, Michaela L Tsai, Thomas A Jandl, Izidore S Lossos iD, Vaishalee P Kenkre, Farrukh Awan iD, William Novotny, Jane Huang und 4 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19419 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Jacob D Soumerai und 15 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Lymphoma, Follicular, Pyrimidines, Pyrazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Lymphoma Research Foundation, Memorial Sloan-Kettering Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of the phosphatidylinositol 3‐kinase delta (PI3Kδ) inhibitor zandelisib with the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib was hypothesized to be synergistic and prevent resistance to single‐agent therapy. This phase 1 study (NCT02914938) included a dose‐finding stage in patients with relapsed/refractory (R/R) B‐cell malignancies ( n = 20) and disease‐specific expansion cohorts in follicular lymphoma (FL; n = 31) or mantle cell lymphoma (MCL; n = 19). The recommended phase 2 dose was zandelisib 60 mg on Days 1–7 plus zanubrutinib 80 mg twice daily continuously in 28‐day cycle. In the total population, the most common adverse events (AEs; all grades/grade 3–4) were neutropenia (35%/24%), diarrhoea (33%/2%), thrombocytopenia (32%/8%), anaemia (27%/8%), increased creatinine (25%/0%), contusion (21%/0%), fatigue (21%/2%), nausea (21%/2%) and increased aspartate aminotransferase (24%/6%). Three patients discontinued due to AEs. The overall response rate was 87% (complete response [CR] = 33%) for FL and 74% (CR = 47%) for MCL. The median duration of response and progression‐free survival (PFS) were not reached in either group. The estimated 1‐year PFS was 72.3% (95% confidence interval [CI], 51.9–85.1) for FL and 56.3% (95% CI, 28.9–76.7) for MCL (median follow‐up: 16.5 and 10.9 months respectively). Zandelisib plus zanubrutinib was associated with high response rates and no increased toxicity compared to either agent alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellLymphoma, FollicularPyrimidinesPyrazolesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleAgedMiddle AgedAdultThiazolesAged, 80 and overAgammaglobulinaemia Tyrosine KinaseTreatment OutcomePiperidines

Stichwörter der Autor:innen

clinical trialfollicular lymphomamantle cell lymphomazandelisibzanubrutinib

Substanzen

zanubrutinibPyrimidinesPyrazolesThiazolesAgammaglobulinaemia Tyrosine KinasePiperidines

Autor:innen und Institutionen

  • Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
  • Perlmutter Cancer Center at NYU Langone Health, New York, New York, USA.
  • Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA.
  • Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • University of Arizona, Tucson, Arizona, USA.
  • Swedish Cancer Institute, Seattle, Washington, USA.

ORCID-Profile: Jacob D Soumerai, Catherine S Diefenbach, Izidore S Lossos, Farrukh Awan

Förderung

  • NCI NIH HHS
  • Lymphoma Research Foundation
  • Memorial Sloan-Kettering Cancer Center
  • National Cancer Institute
  • BeiGene
  • MEI Pharma

Zitieren

APA

Soumerai, J. D., Diefenbach, C. S., Jagadeesh, D., Asch, A., Kumar, A., Tsai, M. L., Jandl, T. A., Lossos, I. S., Kenkre, V. P., Awan, F., Novotny, W., Huang, J., Miao, L., Rajagopalan, P., Ghalie, R. G., & Zelenetz, A. D. (2024). Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. British Journal of Haematology. https://doi.org/10.1111/bjh.19419

Vancouver

Soumerai JD, Diefenbach CS, Jagadeesh D, Asch A, Kumar A, Tsai ML, et al. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. British Journal of Haematology. 2024. doi:10.1111/bjh.19419

BibTeX
@article{Soumerai2024,
  author = {Soumerai, Jacob D and Diefenbach, Catherine S and Jagadeesh, Deepa and Asch, Adam and Kumar, Abhijeet and Tsai, Michaela L and Jandl, Thomas A and Lossos, Izidore S and Kenkre, Vaishalee P and Awan, Farrukh and Novotny, William and Huang, Jane and Miao, Lu and Rajagopalan, Prabhu and Ghalie, Richard G and Zelenetz, Andrew D},
  title = {Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19419}
}
Kostenlos starten →